Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Greywolf Capital
Oxford, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead candidate GRWD5769, an oral ERAP1 inhibitor, is in ongoing adaptive Phase 1/2 trial (EMITT1) in solid tumors, demonstrating proof-of-mechanism and target engagement; first clinical data presented at ASCO 2024.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Pfizer VenturesRegeneron (clinical supply agreement for Libtayo combination)ICG Life SciencesAndera PartnersCanaanEarlybird Venture CapitalOxford Science EnterprisesBritish Patient Capital
Beyond the preview
Go deeper on Greywolf Capital.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Greywolf Capital.